Donepezil is NOT Appropriate for Cognitive Enhancement in Healthy Individuals
Donepezil should not be used for cognitive enhancement in healthy individuals—the evidence shows it provides no benefit and may actually impair cognitive function in this population. The drug is FDA-approved exclusively for treating dementia (Alzheimer's disease, vascular dementia, and related conditions), not for enhancing normal cognition 1.
Why Donepezil Fails as a Cognitive Enhancer
Evidence in Healthy Populations Shows Harm, Not Benefit
The research examining donepezil in healthy individuals reveals concerning findings:
Cognitive impairment occurred in healthy older adults: A rigorous study using EEG and simultaneous EEG/fMRI demonstrated that donepezil (5 mg/day) significantly impaired memory performance in healthy older participants at 6-hour, 2-week, and 4-week follow-ups. The drug negatively affected paired associates learning and altered brain activity in the hippocampus and frontal-parietal networks 2.
Transient worsening of cognitive function: In a double-blind study of 27 healthy adults, donepezil caused subjects to perform "slightly but significantly worse on some tests of speed, attention and memory" compared to placebo, with no improvement observed at any time point 3.
Mixed results at best: While one small study showed modest improvements in some memory tasks in healthy young volunteers 4, and another detected changes in spatial working memory 5, these findings are inconsistent and far outweighed by evidence of harm.
The Drug Only Works in Disease States
The FDA label and clinical guidelines are unequivocal: donepezil demonstrates efficacy only in patients with diagnosed dementia 1. The 2008 American College of Physicians/American Academy of Family Physicians guidelines confirm that:
Donepezil shows statistically significant improvements in cognition (ADAS-cog) and global function (CIBIC-plus) in patients with Alzheimer disease and vascular dementia 6, 7.
For mild cognitive impairment (a pre-dementia state), donepezil showed "no benefit" with effects disappearing by 36 months 7.
The improvements seen in dementia patients, while statistically significant, were often "not clinically important" with average ADAS-cog changes not reaching the clinically significant threshold of ≥4 points 6.
The Mechanism Explains the Failure
Donepezil works by inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the brain. This mechanism addresses the cholinergic deficit present in Alzheimer's disease. In healthy individuals with normal acetylcholine function, artificially elevating these levels disrupts optimal neurotransmitter balance rather than enhancing it, explaining the observed cognitive impairments 2.
Critical Pitfalls to Avoid
The media hype is misleading: A systematic analysis revealed that claims about donepezil as a cognitive enhancer were based on gross misinterpretation of a single small study in pilots. The media and even bioethics literature made "strong claims" and used "enhancement language" that was not supported by the actual study results 8. This represents a cautionary tale about how evidence can be distorted.
Side effects matter: Even in approved dementia populations, donepezil causes gastrointestinal problems (nausea, vomiting, diarrhea), dizziness, and agitation, with withdrawal rates of 0-57% in treatment groups 6, 7. Healthy individuals would experience these adverse effects without any cognitive benefit.
The Bottom Line
Use donepezil only for its FDA-approved indication: treatment of mild to moderate or moderate to severe Alzheimer's disease 1, 9. The most recent evidence (2024-2025) continues to support its use in dementia patients at 5-10 mg/day doses 9, 10, but there is no legitimate role for this medication in healthy individuals seeking cognitive enhancement. The risk-benefit ratio is unequivocally unfavorable in non-diseased populations, with documented cognitive harm and no demonstrated benefit 2.